natgillin/translations-raw huggingface dataset:
• Tell your caregiver that you are taking Rivastigmine 1 A Pharma. 
• Recite osobi koja Vas njeguje da uzimate Rivastigmin 1 A Pharma.
Rivastigmine 1 A Pharma 3 mg and 6 mg hard capsules: 
Rivastigmin 1 A Pharma 3 mg i 6 mg tvrde kapsule:
One of the inactive ingredients in Rivastigmine 1 A Pharma oral solution is sodium benzoate. 
Jedan od neaktivnih sastojaka oralne otopine Rivastigmin 1 A Pharma je natrijev benzoat.
Date of first authorisation: 11/12/2009 Date of first renewal: 19/08/2014 
Datum prvog odobrenja: 11.12.2009.
- Capsule fill: - Microcrystalline cellulose - Magnesium stearate - Hypromellose - Silica, colloidal anhydrous 
- magnezijev stearat - hipromeloza - silicijev dioksid, koloidni, bezvodni
If you are pregnant, the benefits of using Rivastigmine 1 A Pharma must be assessed against the possible effects on your unborn child. Rivastigmine 1 A Pharma should not be used during pregnancy unless clearly necessary. 
Ako ste trudni, koristi primjene Rivastigmina 1 A Pharma moraju se procijeniti u odnosu na moguće djelovanje na nerođeno dijete.
The active substance of Rivastigmine 1 A Pharma is rivastigmine. 
Djelatna tvar Rivastigmina 1 A Pharma je rivastigmin.
D. CONDITIONS OR RESTRICTIONS WITH REGARDS TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU
How to take Rivastigmine 1 A Pharma 
Kako uzimati Rivastigmin 1 A Pharma
One of the excipients in Rivastigmine 1 A Pharma oral solution is sodium benzoate. 
Jedna od pomoćnih tvari oralne otopine Rivastigmin 1 A Pharma je natrijev benzoat.
Package leaflet: Information for the patient Rivastigmine 1 A Pharma 2 mg/ml oral solution 
Uputa o lijeku: Informacija za bolesnika Rivastigmin 1 A Pharma 2 mg/ml oralna otopina rivastigmin
Rivastigmine 1 A Pharma 2 mg/ml oral solution 
Rivastigmin 1 A Pharma 2 mg/ml oralna otopina
Rivastigmine 1 A Pharma might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson's disease or to prevent travel sickness). 
(lijekove koji se koriste za ublažavanje grčeva ili spazama u želucu, za liječenje Parkinsonove bolesti ili za sprečavanje mučnine na putovanju).
Rivastigmine 1 A Pharma 1.5 mg hard capsules: 
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule:
Rivastigmine 1 A Pharma 6 mg 
Rivastigmin 1 A Pharma 6 mg
Each Rivastigmine 1 A Pharma 6 mg capsule contains 6 mg of rivastigmine. 
Svaka kapsula Rivastigmina 1 A Pharma od 6 mg sadrži 6 mg rivastigmina.
Rivastigmine 1 A Pharma 3 mg 
Rivastigmin 1 A Pharma 3 mg
How to store Rivastigmine 1 A Pharma 
Kako čuvati Rivastigmin 1 A Pharma
Each Rivastigmine 1 A Pharma 4.5 mg capsule contains 4.5 mg of rivastigmine. 
Svaka kapsula Rivastigmina 1 A Pharma od 4,5 mg sadrži 4,5 mg rivastigmina.
Each Rivastigmine 1 A Pharma 3 mg capsule contains 3 mg of rivastigmine. 
Svaka kapsula Rivastigmina 1 A Pharma od 3 mg sadrži 3 mg rivastigmina.
Each Rivastigmine 1 A Pharma 1.5 mg capsule contains 1.5 mg of rivastigmine. 
Svaka kapsula Rivastigmina 1 A Pharma od 1,5 mg sadrži 1,5 mg rivastigmina.
Some people who have accidentally taken too much Rivastigmine 1 A Pharma have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. 
Pharma su osjećali mučninu, povraćali, imali proljev, visoki krvni tlak i halucinacije.
Rivastigmine 1 A Pharma 4.5 mg 
Rivastigmin 1 A Pharma 4,5 mg
Rivastigmine 1 A Pharma 4.5 mg hard capsules: 
Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule:
Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10% improvement on the PDS. 
4 boda na ADAS-Cog ljestvici, poboljšanje na CIBIC-Plus ili poboljšanje od najmanje 10% na PDS ljestvici.
Rivastigmine 1 A Pharma 1.5 mg 
Rivastigmin 1 A Pharma 1,5 mg
Each ml contains rivastigmine hydrogen tartrate corresponding to 2mg rivastigmine. 
Svaki ml sadrži rivastigmin hidrogentartarat koji odgovara 2 mg rivastigmina.
• Allergic reaction where the patch was used, such as blisters or skin inflammation If you get any of these side effects, contact your doctor as you may need medical assistance. 
• Alergijska reakcija kod primjene flastera, kao što su plikovi ili upala kože
Each capsule contains rivastigmine hydrogen tartrate corresponding to 6 mg rivastigmine. 
Svaka kapsula sadrži rivastigmin hidrogentartarat koji odgovara 6 mg rivastigmina.
Rivastigmine 1 A Pharma 2 mg/ml oral solution rivastigmine (as hydrogen tartrate) 
Rivastigmin 1 A Pharma 2 mg/ml oralna otopina rivastigmin (u obliku rivastigmin hidrogentartarata)
Only for carton box: Rivastigmine 1 A Pharma 2 mg/ml 
Samo za kartonsku kutiju: Rivastigmin 1 A Pharma 2 mg/ml
- Rivastigmine 1 A Pharma 1.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a yellow cap and yellow body, with a red imprint “RIV 1.5 mg” on the body. 
- Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule, koje sadrže bjelkasti do žućkasti prašak, imaju žutu kapicu i žuto tijelo s crvenom oznakom „RIV 1,5 mg“.
Only for carton box: Rivastigmine 1 A Pharma 6 mg 
Samo za kartonsku kutiju: Rivastigmin 1 A Pharma 6 mg
Rivastigmine 1 A Pharma 4.5 mg hard capsules rivastigmine (as hydrogen tartrate) 
Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule rivastigmin (u obliku rivastigmin hidrogentartarata)
Rivastigmine 1 A Pharma 6 mg hard capsules rivastigmine (as hydrogen tartrate) 
Rivastigmin 1 A Pharma 6 mg tvrde kapsule rivastigmin (u obliku rivastigmin hidrogentartarata)
Only for carton box: Rivastigmine 1 A Pharma 4.5 mg 
Samo za kartonsku kutiju: Rivastigmin 1 A Pharma 4,5 mg
Rivastigmine 1 A Pharma oral solution is supplied as 50 ml or 120 ml of a clear, yellow solution (2.0 mg/ml base) in an amber glass bottle with a child-resistant cap, foam liner, dip tube and self aligning plug. 
Oralna otopina Rivastigmin 1 A Pharma isporučuje se kao bistra, žuta otopina od 50 ml ili 120 ml
Only for carton box: Rivastigmine 1 A Pharma 1.5 mg 
Samo za kartonsku kutiju: Rivastigmin 1 A Pharma 1,5 mg
- Rivastigmine 1 A Pharma 4.5 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and red body, with a white imprint “RIV 4.5 mg” on the body. 
- Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule, koje sadrže bjelkasti do žućkasti prašak, imaju crvenu kapicu i crveno tijelo s bijelom oznakom „RIV 4,5 mg“.
Rivastigmine 1 A Pharma 6 mg hard capsules: EU/1/09/585/013 
Rivastigmin 1 A Pharma 6 mg tvrde kapsule: EU/1/09/585/013
Only for carton box: Rivastigmine 1 A Pharma 3 mg 
Samo za kartonsku kutiju: Rivastigmin 1 A Pharma 3 mg
Rivastigmine 1 A Pharma 3 mg hard capsules rivastigmine (as hydrogen tartrate) 
Rivastigmin 1 A Pharma 3 mg tvrde kapsule rivastigmin (u obliku rivastigmin hidrogentartarata)
- Rivastigmine 1 A Pharma 6 mg hard capsules, which contain an off-white to slightly yellow powder, have a red cap and orange body, with a red imprint “RIV 6 mg” on the body. 
- Rivastigmin 1 A Pharma 6 mg tvrde kapsule, koje sadrže bjelkasti do žućkasti prašak, imaju crvenu kapicu i narančasto tijelo s crvenom oznakom „RIV 6 mg“.
Rivastigmine 1 A Pharma 1.5 mg hard capsules rivastigmine (as hydrogen tartrate) 
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule rivastigmin (u obliku rivastigmin hidrogentartarata)
In other cases, rivastigmine has been discontinued (see section 4.8). 
U takvim slučajevima liječenje treba prekinuti (vidjeti dio 4.3).
Rivastigmine 1 A Pharma 4.5 mg hard capsules: EU/1/09/585/009 
Rivastigmin 1 A Pharma 4,5 mg tvrde kapsule: EU/1/09/585/009
Rivastigmine 1 A Pharma 3 mg hard capsules: EU/1/09/585/005 
Rivastigmin 1 A Pharma 3 mg tvrde kapsule: EU/1/09/585/005
Rivastigmine 1 A Pharma 1.5 mg hard capsules: EU/1/09/585/001 
Rivastigmin 1 A Pharma 1,5 mg tvrde kapsule: EU/1/09/585/001
- Rivastigmine 1 A Pharma 3 mg hard capsules, which contain an off-white to slightly yellow powder, have an orange cap and orange body, with a red imprint “RIV 3 mg” on the body. 
- Rivastigmin 1 A Pharma 3 mg tvrde kapsule , koje sadrže bjelkasti do žućkasti prašak, imaju narančastu kapicu i narančasto tijelo s crvenom oznakom „RIV 3 mg“.
Table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted with rivastigmine in patients with dementia associated with Parkinson's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms. 
tjedna, provedenog s rivastigminom u bolesnika s demencijom povezanom s Parkinsonovom bolešću, pri čemu su nuspojave, koje bi mogle odražavati pogoršanje simptoma parkinsonizma, bile unaprijed definirane.
Dementia associated with Parkinson's Disease 
Parkinsonovom bolešću
Parkinsonism 
Parkinsonove bolesti)
Each ml contains 2.0 mg of rivastigmine (as hydrogen tartrate). 
Svaki ml sadrži 2 mg rivastigmina u obliku rivastigmin hidrogentartarata.
Patients with clinically significant renal or hepatic impairment might experience more adverse reactions (see sections 4.2 and 5.2). 
Nisu proučavani bolesnici s teškim oštećenjem jetre, no kapsule rivastigmina mogu se koristiti u ovoj populaciji bolesnika uz pažljivo praćenje (vidjeti dijelove 4.4 i 5.2).
- if you have, or have ever had impaired kidney function. 
- ako imate ili ste imali nepravilne ili spore otkucaje srca,
Date of first authorisation: 18 January 2018 
Datum prvog odobrenja: 18. siječnja 2018.
Type AE 
Tip AE
Type C 
Tip C
HIV PI darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir 
Inhibitori proteaze (IP) darunavir amprenavi atazanavir indinavir lopinavir sakvinavir tipranavir
TAD Pharma GmbH Heinz-Lohmann-Straβe 5 27472 Cuxhaven Germany 
TAD Pharma GmbH Heinz-Lohmann-Straβe 5 27472 Cuxhaven Njemačka
Cobicistat is not indicated for use in twice daily regimens or for use in the paediatric population. 
Kobicistat nije indiciran za primjenu u režimu doziranja dvaput na dan ili za primjenu u pedijatrijskoj populaciji.
Ethinylestradiol/drospirenone. 
- etinilestradiol/drospirenon.
Metformin (to treat type 2 diabetes). 
- metformin (za liječenje šećerne bolesti tipa 2).
Take two 400 milligram tablets at the same time or one 800 miligram tablet, once a day, every day. 
- Uzimite dvije tablete od 400 miligrama u isto vrijeme ili jednu tabletu od 800 miligrama, jedanput na dan, svaki dan.
section 4.3). 
(vidjeti dio 4.3).
The effects of Darunavir Krkad.d.might be reduced if you take any of the following products. 
Učinci lijeka Darunavir Krka d.d. mogu se smanjiti ako uzimate bilo koji od sljedećih lijekova.
If you belong to this age group, please discuss with your doctor if you can use Darunavir Krka d.d.. 
Ako pripadate toj dobnoj skupini, molimo Vas da s liječnikom razmotrite smijete li uzimati lijek Darunavir Krka d.d.
The dose of cobicistat to be used with darunavir has not been established in this patient population. 
Doza kobicistata koja se uzima s darunavirom nije bila ustanovljena u ovoj populaciji bolesnika.
Of the 44 patients taking ritonavir oral solution, 27 switched to the 100 mg capsule formulation and exceeded the weight based ritonavir dose without changes in observed safety. 
Od 44 bolesnika koji su uzimali ritonavir oralnu otopinu, njih 27 prešlo je na 100 mg kapsule i time prešlo preporučeno doziranje na temelju tjelesne težine, a da pri tome nisu opažene promjene u sigurnosti.
Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk (see sections 4.4, 4.6 and 5.2). 
Darunavir/ritonavir se smiju uzimati tijekom trudnoće samo ako potencijalna korist opravdava potencijalni rizik (vidjeti dijelove 4.4, 4.6 i 5.2).
Darunavir Krka d.d.might increase sugar levels in the blood. 
Darunavir Krka d.d. može povisiti razine šećera u krvi.
When used for birth control, alternative methods of nonhormonal contraception are recommended. 
Za zaštitu od začeća, preporučuju se drugi oblici nehormonske kontracepcije.
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS 
INTERAKCIJE I PREPORUČENE DOZE S DRUGIM LIJEKOVIMA
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Darunavir Krka d.d.. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Darunavir Krka d.d.
withany of the following medicines If you are taking any of these, ask your doctor about switching to another medicine. 
Ako uzimate neki od navedenih lijekova, pitajte svog liječnika o prebacivanju na drugi lijek.
What you need to know before you take Darunavir Krka d.d. 
Što morate znati prije nego počnete uzimati Darunavir Krka d.d.
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS For the treatment of erectile dysfunction 
INHIBITORI FOSFODIESTERAZE, TIP 5 (PDE-5) Za liječenje erektilne disfunkcije Avanafil
What Darunavir Krka d.d.looks like and contents of the pack Darunavir Krka d.d.400mg film-coated tablets (tablets): 
Kako Darunavir Krka d.d. izgleda i sadržaj pakiranja Darunavir Krka d.d. 400 mg filmom obložene tablete (tablete):
cannot work properly without cobicistat or ritonavir and food. 
Darunavir Krka d.d. ne može pravilno djelovati bez kobicistata ili ritonavira i hrane.
Darunavir demonstrates antiviral activity in vitroagainst a broad panel of HIV-1 group M (A, B, C, D, E, F, G) and group O primary isolates with EC50values ranging from < 0.1 to 4.3 nM. 
Darunavir pokazuje antivirusnu aktivnost in vitro protiv širokog panela HIV-1 skupine M (A, B, C, D, E, F, G) i skupine O primarno izolata s EC50 vrijednostima u rasponu od < 0,1 do 4,3 nM.
with food and drink See section 3 ‘How to take Darunavir Krka d.d..' 
Darunavir Krka d.d. s hranom i pićem Vidjeti dio 3 „Kako uzimati Darunavir Krka d.d.“
600 mg film coated tablets must not be chewed or crushed. 
Darunavir Krka d.d. 600 mg filmom obložene tablete ne smiju se žvakati ili lomiti.
Darunavir Krkad.d.has only been used in limited numbers of patients 65 years or older. 
Darunavir Krka d.d. je primjenjivan samo u ograničenog broja bolesnika u dobi od 65 godina ili starijih.
Cobicistat as a pharmacokinetic enhancer of darunavir should, therefore, not be initiated in patients with creatine clearance less than 70 ml/min if any co-administered agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine, lamivudine, tenofovir disoproxil (as fumarate, phosphate or succinate) or adefovir dipovoxil. 
Prema tome, kobicistat koji se koristi kao farmakokinetički pojačivač darunavira ne smije se početi davati bolesnicima s klirensom kreatinina manjim od 70 ml/min, ako bilo koji od istodobno primijenjenih lijekova zahtjeva prilagodbu doze temeljenu na klirensu kreatinina: npr. emtricitabin, lamivudin, tenofovir dizoproksil (u obliku fumarata, fosfata ili sukcinata) ili adefovir dipovoksil.
Darunavir Krkad.d.cannot work properly without food. 
Darunavir Krka d.d. ne može pravilno djelovati bez hrane.
Baseline genotype or phenotype and virologic outcome Baseline genotype and darunavir FC (shift in susceptibility relative to reference) were shown to be a predictive factor of virologic outcome. 
Početni genotip ili fenotip i virološki ishod Početni genotip i PV darunavira (promjena u osjetljivosti u odnosu na referentnu vrijednost) pokazali su se predikcijskim faktorima virološkog ishoda.
What Darunavir Krka d.d.contains -The active substance is darunavir. 
Što Darunavir Krka d.d. sadrži - Djelatna tvar je darunavir.
The increased exposure to darunavir in HIV-1 infected patients compared to healthy subjects may be explained by the higher concentrations of α1-acid glycoprotein (AAG) in HIV-1 infected patients, resulting in higher darunavir binding to plasma AAG and, therefore, higher plasma concentrations. 
Povišena izloženost darunaviru u bolesnika inficiranih s HIV-1 u usporedbi sa zdravim ispitanicima može se objasniti višim koncentracijama α1-kiselog glikoproteina (AAG, od engl. α1-acid glycoprotein) u bolesnika inficiranih s HIV-1, što može rezultirati višim vezivanjem darunavira na AAG u plazmi i stoga višim koncentracijama u plazmi.
• For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 
- Za liječenje HIV-1 infekcije u pedijatrijskih bolesnika u dobi od 3 godine i težine najmanje 15 kg.
Virogic failures were defined as: never suppressed: confirmed HIV-1 RNA < 1 log10 reduction from baseline and ≥ 50 copies/ml at the week-8; rebound: HIV-1 RNA < 50 copies/ml followed by confirmed HIV-1 RNA to ≥ 400 copies/ml or confirmed > 1 log10 HIV-1 RNA increase from the nadir; discontinuations with HIV-1 RNA ≥ 400 copies/ml at last visit IAS-USA lists In GS-US216-130 baseline phenotype was not available 
Virološki neuspjeh definiran je kao: nikad suprimiran: potvrđena HIV-1 RNK < 1 log10 smanjenje u odnosu na početnu vrijednost i ≥ 50 kopija/ml u 8.tjednu; povratak: HIV-1 RNK < 50 kopija/ml nakon čega slijedi potvrđena HIV-1 RNK do ≥ 400 kopija/ml ili potvrđeni > 1 log10 HIV-1 RNK porast u odnosu na najnižu točku (od engl.nadir); prekid liječenja sa HIV-1 RNK ≥ 400 kopija/ml pri zadnjoj posjeti IAS-USA liste U GS-US216-130 fenotip na početku nije bio dostupan
Co-administration with strong CYP3A4 inhibitors is not recommended and caution is warranted, these interactions are described in the interaction table below (e.g. indinavir, azole antifungals like clotrimazole). 
inhibitorima se ne preporučuje i savjetuje se oprez, ove interakcije opisane su u tablici interakcija ispod (npr. indinavir, antifungalni azoli poput klotrimazola).
Based on normal approximation to the difference in % response Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0 
Na temelju normalne aproksimacije razlike u % odgovora Bolesnik koji nije završio ispitivanje zabilježen je kao neuspjeh: bolesnicima koji su prijevremeno prekinuli ispitivanje pripisana je promjena jednaka 0
Refer to section 4.4 if creatinine clearance is used for dose adjustment of tenofovir disoproxil. 
Pogledajte dio 4.4 ako se klirens kreatinina koristi za prilagodbu doze tenofovir dizoproksila.
twice daily the child must take one dose in the morning, and one dose in the evening. 
Ako je Darunavir Krka d.d. propisan dvaput na dan dijete mora uzeti jednu dozu ujutro, a jednu dozu navečer.
Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone) 
KORTIKOSTEROIDI Kortikosteroidi prvenstveno metabolizirani putem CYP3A (uključujući betametazon, budezonid, flutikazon, mometazon, prednizon, triamcinolon)
if you are allergic to active substance or any of the other ingredients of this medicine (listed in section 6), if you have severe liver problems. 
Nemojte uzimati Darunavir Krka d.d. - ako ste alergični na djelatnu tvar ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.), - ako imate teške jetrene tegobe.
When administration of atorvastatin and boosted darunavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily. 
Kada se želi primijeniti atorvastatin i pojačan darunavir, preporučuje se početi s dozom atorvastatina od 10 mg jedanput na dan.
400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). 
Darunavir Krka d.d. od 400 mg i 800 mg tablete mogu se primjenjivati da bi se osigurali prikladni režimi doziranja za liječenje HIV-1 infekcije u odraslih i pedijatrijskih bolesnika od 3 godine starosti i tjelesne težine barem 40 kg koji: - nisu prethodno liječeni antiretrovirusnom terapijom (ART) (vidjeti dio 4.2).
tablets and how much ritonavir (capsules, tablets or solution) the child must take. 
Liječnik će odrediti koliko tableta lijeka Darunavir Krka d.d. i koliko ritonavira (kapsula, tableta ili otopine) dijete mora uzimati.
In contrast to these data with darunavir /ritonavir, darunavir/cobicistat may increase these antidepressant plasma concentrations (CYP2D6 and/or CYP3A inhibition). 
Suprotno u odnosu na ove podatke s darunavirom/ritonavirom, darunavir/kobicistat može povisiti koncentracije tih antidepresiva u plazmi (CYP2D6 i/ili CYP3A inhibicija).
Low rates of developing resistant HIV-1 virus were observed in ART-naïve patients who are treated for the first time with darunavir/cobicistat once daily in combination with other ART, and in ARTexperienced patients with no darunavir RAMs receiving darunavir/cobicistat in combination with other ART. 
Niske stope razvijanja rezistentnog HIV-1 virusa bile su uočene u bolesnika koji prethodno nisu liječeni ART-om i koji su liječeni prvi put s darunavirom/kobicistatom jedanput na dan u kombinaciji s drugim ART-om, i u bolesnika koji su prethodno liječeni ART-om bez mutacija povezanih s rezistencijom (RAM) na darunavir koji primaju darunavir/kobicistat u kombinaciji s drugim ART-om.
Darunavir/ritonavir 10 kg to < 15 kg N=5 
Ishodi u 48 tjednu darunavir/ritonavir 10 kg do < 15 kg N=5
Outcomes darunavir/ritonavir 
darunavir/ritonavi
Patients should be instructed to take darunavir with cobicistat or low dose ritonavir within 30 minutes after completion of a meal. 
Bolesnike se mora uputiti da uzimaju darunavir s kobicistatom ili niskom dozom ritonavira unutar 30 minuta nakon završetka obroka.
Other medicines and Darunavir Krka d.d. 
Drugi lijekovi i Darunavir Krka d.d.
One ritonavir a dose is between 15 and 30 kilograms 600 milligram 
Jedna doza darunavira je Jedna doza ritonavira a je između 15 i 30 kilograma 600 miligrama
For use in these patients, more suitable formulations containing darunavir should be checked for their availability. 
Za primjenu u tih bolesnika potrebno je provjeriti dostupnost prikladnijih oblika koji sadrže darunavir.
Atorvastatin 10 mg once daily atorvastatin AUC ↑ 3-4 fold atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin Cmax ↑ ≈2 fold darunavir/ritonavir atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin ND 
Atorvastatin 10 mg jedanput na dan atorvastatin AUC ↑ 3-4 puta atorvastatin Cmin ↑ ≈5.5-10 puta atorvastatin Cmax ↑ ≈2 puta darunavir/ritonavir atorvastatin AUC ↑ 290% atorvastatin Cmax ↑ 319% atorvastatin Cmin NO
400 or 800 milligram tablet is not for use in children younger than 3 years of age or weighing less than 40 kilograms. 
Tableta lijeka Darunavir Krka d.d. od 400 miligrama ili 800 miligrama nije namijenjena za primjenu u djece mlađe od 3 godine ili tjelesne težine manje od 40 kilograma.
600 mg tablets can be used to construct the twice daily 600 mg regimen. 
Darunavir Krka d.d. od 600 mg tablete mogu se primijeniti za dostizanje režima doziranja od 600 mg dvaput na dan.
Even when you feel better, do not stop taking Darunavir Krka d.d.. Talk to your doctor first. 
Čak i ako se osjećate bolje, nemojte prestati uzimati lijek Darunavir Krka d.d. Najprije razgovarajte sa svojim liječnikom.
without talking to your doctor first Anti-HIV medicine may make you feel better. 
Uz lijekove protiv HIV-a možete se početi osjećati bolje.
Clinical monitoring is recommended when co-administering boosted darunavir with these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be considered. 
Preporučuje se kliničko praćenje kada se istodobno primjenjuje darunavir s tim sedativima/hipnoticima i u obzir treba uzeti nižu dozu sedativa/hipnotika.
The maraviroc dose should be 150 mg twice daily when co-administered with darunavir with low dose ritonavir. 
Doza maraviroka mora biti 150 mg dvaput na dan kada se primjenjuje istodobno s darunavirom s niskom dozom ritonavira.
In patients taking Darunavir Krka d.d.and raltegravir (for HIV infection), rashes (generally mild or moderate) may occur more frequently than in patients taking either medicine separately. 
U bolesnika koji uzimaju Darunavir Krka d.d. i raltegravir (za HIV infekciju) u kombinaciji, osipi (obično blagi ili umjereni) mogu se javiti češće nego u bolesnika koji uzimaju samo jedan od ovih lijekova.
These patients received darunavir 800 mg once daily in combination with cobicistat 150 mg once daily with an investigator selected background regimen consisting of 2 active NRTIs. 
Ovi bolesnici su primali darunavir 800 mg jedanput na dan u kombinaciji s kobicistatom od 150 mg jedanput na dan s osnovnim liječenjem koje je uključilo 2 aktivna NRTI-ja po izboru ispitivača.